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Abstract
Mutations in the telomerase reverse transcriptase gene promoter (TERTp) are common in glioblastomas (GBMs) and
oligodendrogliomas (ODGs), and therefore, have a key role in tumorigenesis and may be of prognostic value. However,
the extent of their prognostic importance in various gliomas is controversial. We studied 168 patients separated into five
groups: Group 1: 65 patients with ODG carrying an IDH1 or IDH2 mutation (IDH-mutant) and 1p/19q–codeletion, Group 2:
23 patients with anaplastic astrocytoma (AA), IDH-mutant, Group 3: 13 patients with GBM, IDH-mutant, Group 4: 15 patients
with AA, IDH-wildtype (WT), and Group 5: 52 patients with GBM, IDH-WT. TERTp mutations were found in 96.9%, 4.4%, 76.
9%, 20.0%, and 84.6% of patients in Groups 1, 2, 3, 4, and 5, respectively. The R132H mutation in IDH1 was found in 60.5%
(23/38) of patients in the AA cohort (Groups 2 and 4) and 20.0% (13/65) of patients from our GBM cohort (Groups 3 and 5),
whereas all patients with ODG (Group 1) had a mutation either in IDH1 (n= 62) or IDH2 (n= 3). Using Kaplan Meier survival
analysis, we found that the TERTp mutation was correlated with poor overall survival (OS) in Groups 2 and 4 combined
(P= 0.001) and in Group 4 (P = 0.113), and in multivariate analysis, the TERTp mutant group was associated
with significantly poor survival in Group 5 (P = 0.045). However, IDH mutation, MGMT methylation, and younger patient
age (<55 years old) were significantly correlated with favorable OS (all P < 0.05) in our cohort of astrocytic and ODGs. In
patients with ODG (Group 1), mutant IDH and TERTp did not have prognostic value because these mutations were
universally present. Based on the revised 2016 WHO classification of gliomas, we found that TERTp mutation was frequently
present in patients with GBM or ODG and because it was strongly correlated with poor survival outcome in patients with
IDH-WT GBM in multivariate analysis, it may be of prognostic value in this subgroup of patients with gliomas.
Keywords: Telomerase reverse transcriptase, Alpha-thalassemia/mental retardation syndrome X-linked (ATRX) , Anaplastic
astrocytoma, Glioblastoma, Isocitrate dehydrogenase (IDH), Oligodendroglioma
Introduction
Gliomas are the most common primary malignant
tumor of the central nervous system (CNS), and are
comprised of diffuse astrocytic and oligodendroglial
tumors (ODG). Significant research in the pathogenesis
of gliomas revealed that various morphological pheno-
types are related to underlying molecular genetic varia-
tions [4, 26]. This understanding has resulted in the
restructuring of glioma classification with the incorpor-
ation of genetically defined entities and histology [19].
Of the many molecular changes found in gliomas, mu-
tations in IDH1 or IDH2 occur early during glioma for-
mation, and are associated with better overall survival
(OS). In addition, glioma subtypes can be identified by
the IDH1/IDH2 mutation [11, 27]. The second most im-
portant genetic alteration is a co-deletion at chromo-
some regions 1p and 19q, which results from a
chromosomal translocation t(1p;19q)(q10;p10), and is
exclusively associated with ODGs and better prognosis
[20]. Such examples demonstrate that the identification
of new molecular genetic changes, which occur during
glioma formation or development, are necessary to bet-
ter guide clinical decision making.
Recently, mutations in the promoter region of the tel-
omerase reverse transcriptase (TERTp) gene have been
found in various cancers, including glioblastomas
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(GBMs) [18] and ODGs [3, 8]. Telomerase activity has a
major role in tumorigenesis [6] and contributes to tumor
development in different brain tumors, including astro-
cytomas, GBMs, and ODGs [12, 17]. The two most com-
mon mutations in the TERTp are C228T and C250T,
which are located −124 base pairs (bp) and −146 bp re-
spectively, upstream of the TERT ATG start site
(chr5p15.33: 1,295,228 C > T and 1,295,250 C > T, re-
spectively) [15]. These mutations confer unrestricted
growth properties to tumor cells by elongation of telo-
mere length because of TERT activation, which indicates
the importance of its role in the anti-senescence and im-
mortal cancer development [2, 7].
It has been reported that the effects of TERTp muta-
tions are inversely correlated with mutations found in
the IDH1 gene, [22] which is a well-known molecular
factor for a favorable prognosis [27]. Therefore, several
studies have independently proposed that mutations in
TERTp are associated with poor prognosis [15]. How-
ever, recently Pekmezci et al. studied TERTp and ATRX
mutation status and their prognostic value in large co-
horts from the UCSF and Mayo clinics and The Cancer
Genome Atlas (TCGA), and found that the wildtype
(WT) TERTp group was associated with good prognosis
only in IDH1/IDH2 WT (IDH-WT) astrocytomas (grade
II and III), while in other groups such as IDH-mutant
astrocytomas (grades II and III) and GBMs (grade IV)
with or without IDH-mutation, TERTp mutation status
was not a statistically significant prognostic factor [23].
In addition, they found that ATRX was a good prognos-
tic factor only in IDH-WT GBMs (grade IV), but not in
any other glioma group [23].
In this study, we examined TERTp mutation status in
a cohort of patients with either diffuse astrocytomas
(grade III or IV) or ODG (grade II or III) to identify the
frequencies of these mutations in our cohort and to
evaluate their potential prognostic value, risk stratifica-
tion, and future target therapy.
Materials and methods
Our cohort consisted of 168 patients in five groups, in-
cluding 65 patients with ODGs carrying an IDH-muta-
tion (IDH-mutant) and 1p/19q–codeletion (termed
Group 1 or the ODG group), 23 patients with anaplastic
astrocytoma (AA), IDH-mutation (Group 2), 13 patients
with GBM, IDH-mutant (Group 3), 15 patients with AA,
IDH-WT (Group 4), and 52 patients with GBM, IDH-
WT (Group 5), which were obtained from the archives
of the Department of Pathology of the Seoul National
University Hospital (SNUH) from 2007 to 2015. All pa-
tients underwent surgery at the Department of Neuro-
surgery at the SNUH. All tumors were reviewed by two
neuropathologists (SH Park and JK Won) according to
the revised 2016 World Health Organization (WHO)
classification of tumours of the CNS [19]. The mean age
of patients with ODG, IDH-mutant AA, IDH-mutant
GBM, IDH-WT AA, and IDH-WT GBM was 43.4, 42.6,
39, 48.6, and 55.3 years, respectively. The male-to-
female ratio of these groups were 1:1, 7.4:2.6, 7:3, 4:6,
and 6.6:3.4, respectively. Therefore, the ODG group had
no gender predominance, but other subtypes had male
predominance except for IDH-WT AA. Clinicopatholog-
ical data were obtained from medical and pathological
records, which are summarized in Table 1. Representa-
tive MRI, hematoxylin and eosin (H&E) features and im-
munohistochemical staining of IDH1 (H09) and ATRX
are demonstrated in Figs. 1 and 2. This study followed
the principles of the World Medical Association Declar-
ation of Helsinki and it was approved by the Institu-
tional Review Board of SNUH (IRB No.: 1307-093-505).
Immunohistochemistry
Formalin-fixed paraffin-embedded (FFPE) tissue blocks
were cut into 3-μm-thick slices and underwent immuno-
histochemistry (IHC). The DO-7 monoclonal antibody
(mAb) for p53 (1:1000, DAKO, Glostrup, Denmark),
sc48817 for Olig2 (1:500, Santa Cruz Biotechnology, Santa
Cruz, US), the anti-human Ki-67 mAb (1:1000, clone
MIB-1, DAKO), ATRX (Merck (Sigma-Aldrich), St Louis,
US), and the mAb against the R132H mutation in IDH1
(1:100, clone H09, Dianova, Heidelberg, Germany) were
used for accurate pathological diagnosis (Table 2). The ap-
propriate positive controls were used and primary anti-
bodies were omitted as negative controls.
Virtual microscope scanning was performed on Ki-67-,
p53-, and Olig2-immunostained slides using the Aperio
Spectrum Plus image analyzer (Leica Biosystems Nus-
sloch GmbH, Nußloch, Germany) and we used them as
an aid when reviewing the diagnosis. Intact tumor areas
of each slide, excluding areas with crush artifacts, necro-
sis, and other poor-quality regions, were evaluated. For
automated quantitation of each marker, nuclear V9 IHC
algorithms of the Aperio Spectrum Plus image analyzer
were applied after validating the data from comparisons
to manual counts in a number of representative cases.
The proportion of cells expressing Ki-67, p53, and Olig2
in the nuclei was calculated as a percentage of the total
number of tumor cell-nuclei. We used a 30% cut off for
p53 positivity.
Fluorescence in situ hybridization for 1p and 19q
FFPE blocks underwent fluorescence in situ
hybridization (FISH). Paired fluorescein isothiocyanate
(FITC)/rhodamine-labeled DNA probes for chromosome
regions 1p (LSI1p36/LSI1q25) and 19q (LSI19q13/
LSI19p13) were used for deletion analysis.
Green and red fluorescent signals were counted under
a BX01 fluorescence microscope (Olympus, Olympus
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No n (%) n (%) n (%) n (%) n (%)
Number of Patients 168 65 (100) 23 (100) 13 (100%) 15 (100%) 52 (100%)
Age (years) Mean (range) 43.4 (21–65) 42.6 (21–65) 39 (29–49) 48.6 (26–72) 55.3 (27–79)
Gender Male 33 (50.8) 17 (73.9) 9 (69.2) 6 (40) 35 (66.0)
Female 32 (49.2) 6 (26.1) 4 (30.8) 9 (60) 17 (34.0)
Mean OS (mo) 38.0 (0–95) 59.4 (0.5–114.8) 40.0 (11.8–72.3) 28.2 (0.5–76.9) 19.6 (0.5–116)
Mean PFS (mo) 38.0 (1–96) 48.7 (0.5–114.8) 36.0 (9.5–68.7) 13.8 (0.5–76.9) 15.4 (0–103)
TERT sequencing Wildtype 2 (3.1) 22 (95.6) 3 (23.1) 12 (80) 11 (21.2)
Mutant 63 (96.9) 1 (4.4) 10 (76.9) 3 (20) 41 78.8)
1p, 19q FISH No co-deletion 0 (0) 0 (0) 13 (100) 15 (100) 53 (100)
Co-deletion 65 (100) 23 (100) 0 (0) 0 (0) 0 (0)












MGMT MSP No methylation 11 (16.9) 9 (39.1) 3 (23.1) 7 (46.7) 26 (50.0)
Methylation 54 (83.1) 14 (60.9) 10 (76.9) 8 (53.3) 26 (50.0)
Ki-67 labeling index (%) Mean (range) 10.6 (1.5–39.5) Not available 14 (1–39.3) Not available 20.6 (0–54.8)
Abbreviations: mo month, OS overall survival, PFS progression free survival, FISH fluorescent in situ hybridization, IHC immunohistochemistry,
MSP methylation-specific PCR, HD homozygous deletion, WHO World Health Organization
Fig. 1 a) MRI showing a solid and cystic mass involving the right frontal lobe with diffuse increased T2 signal intensity in the right frontal lobe,
insula, and corpus callosum genu with subfalcine herniation on the left side. b) The tumor is indicative of glioblastoma by the presence of
necrosis and microvascular proliferation. c, d) Tumor cells are positive for IDH-1 (H09), R132H-mutant, and retained expression of ATRX
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corporation, Japan) using the MetaMorph® Imaging
System (Universal Imaging, Molecular Devices, US). For
each hybridization, the number of green and red signals
was assessed using a minimum of 100 non-overlapping
nuclei. An interpretation of a deletion was made when
>50% of nuclei harbored a single red or green signal.
This determination was based on the frequency of non-
neoplastic nuclei that contained one signal (median ± 3
standard deviations) using the same probes in non-
neoplastic control (seizure-resection) specimens.
IDH1/IDH2 and TERT mutation analysis
Sanger sequencing was used to determine the frequency
of mutations in IDH1, IDH2, and TERT. Primer design
was based on sequence data from accession numbers
NM 005896 for IDH1 and NM 002168 for IDH2
(http://www.ncbi.nlm.nih.gov). Representative H&E
stained slides were reviewed by two pathologists (SH
Park and JK Won), and a selected tumor region was
macrodissected manually from consecutive FFPE
sections. After deparaffinization, genomic DNA was ex-
tracted and underwent nested-PCR for IDH1 (186 bp),
IDH2 (302 bp), and the TERTp. PCR primer sequences
used for IDH1 and IDH2 are summarized in Table 2.
PCR amplification and Sanger sequencing was
performed using an ABI-PRISM 3730 DNA Analyzer
(Applied Biosystems, Vernon Hills, IL, USA). PCR was
performed in 40 μL reaction conditions that included
standard buffer conditions, 200 ng of DNA, and GoTaq
DNA Polymerase (Promega, Madison, WI, USA). PCR
amplification for IDH1 consisted of 45 cycles with de-
naturation at 95 °C for 30 s, followed by annealing at
62 °C for 30 s, and extension at 72 °C for 1 min,
whereas PCR amplification for IDH2 consisted of 40 cy-
cles with denaturing at 95 °C for 30 s, followed by an-
nealing at 55 °C for 30 s, and extension at 72 °C for
1 min. Two microliters of PCR amplification product
were sequenced using the BigDye Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems, Foster City, CA,
USA). Twenty-five cycles were performed using 12 ng
of the sense primers IDH1f 5′-M13-GTAAAACGACG
Fig. 2 Recurrent anaplastic astrocytoma, IDH-mutant. a) MRI showing initial tumor and 3 times recurrent tumors despite concurrent chemotherapy and
radiotherapy. b) Initial tumor showing a sheet of neoplastic gemistocytic astrocytes with mild to moderate nuclear atypia, WHO grade III. c) The second
recurrent tumor shows more pleomorphic nuclei with bizarre tumor cell features than those of initial tumor, but there is neither tumor necrosis nor
microvascular proliferation. c, d) However, note IDH-1 and ATRX mutation were sustained (c: IDH1 (H09) staining, d: ATRX immunostaining)
Table 2 Primary antibodies used in this study
Name Manufacturer Clone Dilution
Glial fibrillary
acid protein
DAKO, Glostrup, Denmark 6F2 1:300
Olig2 Santa Cruz Biotechnology, Santa Cruz,
US
sc48817 1:500
P53 DAKO, Glostrup, Denmark DO7 1:1000
Ki-67 DAKO, Glostrup, Denmark MIB-1 1:1000
IDH1 DIANOVA, Hamburg, Germany DIAH09 1:100
ATRX MERCK (Sigma), St Louis, USA HPA001906 1:100
For antigen retrieval, cell conditioning with CC1 buffer pH 8.4 (Ventana,
Export, PA) was used for all antibodies
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GCCAGTCGGTCTTCAGAGAAGCCA-3′ or IDH2f
5′-GCTGCAGTGGGACCACTATT-3′ with denatur-
ation at 96 °C for 10 s, annealing at 50 °C for 5 s, and
extension at 60 °C for 4 min.
Two hotspot mutations, C228T and C250T, in the
TERTp were screened using the oligonucleotide primers
shown in Table 3. M13 has a universal sequencing pri-
mer site with the sequence 5′-GTAAAACGACGGC
CAGT-3′ that was used for PCR amplification of the
proximal TERTp for Sanger sequencing using standard
methods. PCR was performed in 50 μL reaction
mixtures containing 5 μL of DNA, 10 mM of each
dNTP, 10 pmole/μL each primer, 5X Band Doctor™, 10X
h-Taq Reaction buffer (15 mM MgCl2 mixed), and
2.5 U/μL of Solg™ h-Taq DNA Polymerase. PCR was ini-
tiated at 95 °C for 15 min, followed by 45 cycles of 95 °C
for 30 s, 62 °C for 30 s, and 72 °C for 1 min with a final
extension of 72 °C for 7 min.
Methylation-specific PCR
Methylation status of the O-6-methylguanine-DNA
methyltransferase (MGMT) gene promoter was deter-
mined by extracting tumor genomic DNA from FFPE
sections for bisulfite conversion using the EZ DNA
methylation-Gold Kit (Zymo Research, Orange County,
CA, USA). MGMT methylation-specific PCR was per-
formed using primer pairs specific to methylated and
unmethylated MGMT promoter sequences (Table 3).
Statistical analysis
All statistical analyses were performed using SPSS soft-
ware v23 (IBM Corp., New York, NY, USA). Compari-
sons between variables were performed using the χ2 test,
Fisher’s exact test, or the Student’s t-test. Disease-free
survival (DFS) was measured from the date of surgery to
that of disease recurrence or onset of metastasis. OS was
measured from the date of diagnosis until death from
any cause. Survival analysis was performed using the
Kaplan-Meier method with log-rank test. Multivariate
Cox regression analysis was performed with consider-
ation of co-linearity. Two-sided P-values <0.05 were
considered statistically significant.
Results
TERTp mutation status and relationship with
clinicopathological parameters
Somatic TERTp mutations were analyzed by direct Sanger
sequencing. TERTp mutations were detected in 96.9%,
4.4%, 76.9%, 20.0% and 84.6% of patients in Group 1, 2, 3,
4, and 5, respectively. The C228T mutation was much
more frequent than the C250T mutation in our cohort
(Fig. 3 and Table 4). There was no evidence of an associ-
ation between TERTp mutation and IDH or ATRX muta-
tion (ATRX loss) or MGMTp methylation status, gender
preference, or age preference in all patient groups except
the patients with AA (grade III) by Pearson χ2 test. Fur-
ther, in patients with AA (combined groups 2 and 4), the
TERTp mutation was more common for over 55 years of
age (P = 0.004), which may be the reason why TERTp mu-
tation is an adverse marker specifically for IDH-WT AA.
In this study we could not reach statistical significance (P
= 0.113), because of the lack of the number of TERTp mu-
tant cases (Fig. 5c).
IDH1/IDH2 mutation status and relationship with
clinicopathological parameters
The R132H mutation in IDH1 was found in 60.5%
(23/38) of patients with AA and 20.0% (13/65) of our
patients with GBM (Groups 3 and 5), whereas all pa-
tients with ODG (Group 1) had a mutation either in
IDH1 (n = 62) or IDH2 (n = 3), as determined by
Sanger sequencing. Correlation analysis between IDH
mutation and clinicopathological features in these five
groups of gliomas revealed that IDH mutation was as-
sociated with a younger age at diagnosis and in pa-
tients with MGMT methylation and ATRX mutation,
respectively by Pearson χ2 test, but it was not corre-
lated with TERTp mutation (p < 0.05).
MGMTp methylation and ATRX mutation (ATRX loss) status
MGMTp methylation was present in 83.1% 60.9%,
76.9%, 53.3%, and 49.1% of cases from Groups 1, 2, 3, 4,
to 5, respectively. An ATRX mutation was present in
69.6% 69.2%, 40.0%, and 5.7% of patients from Group 2,
3, 4, to 5 respectively, but it was not found in patients
with ODGs (Group 1). MGMTp methylation was more
Table 3 Primer sequences of IDH1/IDH2, TERT promoter, and MGMT for Sanger sequencing
Prime
Gene Forward Reverse Product (bp)
IDH1 5′-M13-GTA AAA CGA CGG CCA GTC GGT CTT
CAG AGA AGC CA-3′
5′-GCG GAT AAC AAT TTC ACA CAG GGC
AAA ATC ACA TTA TTG C-3′
180–190
IDH2 5′-GCT GCA GTG GGA CCA CTA TT-3′ 5′-TGT GGC GTT GTA CTG CAG AG-3′ 295–305
TERT 5′-M13-GTA AAA CGA CGG CCA GTC ACC CGT
CCT GCC CCT TCA CCT T-3′
(M13: 5′-GTA AAA CGA CGG CCA GT-3′)
5′-GCA CCT CGC GGT AGT GG-3′ 300–310
MGMT 5′-TTT CGA CGT TCG TAG GTT TTC GC-3′ 5′-GCA CTC TTC CGA AAA CGA AAC G-3′ 80–90
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common in IDH-mutant GBMs, but was not associated
with IDH mutation status in AA. ATRX mutation was
also more common in IDH-mutant GBMs and/or youn-
ger patient under 55 years old with GBM.
Prognostic impact of TERTp, ATRX, and IDH mutations,
and MGMTp methylation
Using Kaplan-Meier survival analysis, we found that
these five groups were well segregated (P = 0.000)
(Fig. 4a) and patients with IDH-mutant gliomas had
significantly better survival compared to those with
IDH-WT gliomas (P < 0.001, P < 0.003) (Fig. 4b and
c).
In addition, we found that MGMTp methylation
was a good prognostic factor in pooled groups with
total GBM (Groups 3 and 5) (P = 0.008) and total AA
and GBM groups (groups 2, 3, 4, and 5 combined)
(P = 0.017) (Fig. 4d); however, in individual groups of
gliomas, MGMTp methylation was not correlated with
OS. In IDH-mutant and IDH-WT GBMs (Groups 3
and 5), we found that MGMTp methylation was a
borderline indicator of better prognosis (P = 0.051 and
0.076) (Fig. 4e-f ). In total AA (Groups 2 and 4),
MGMTp methylation was not correlated with survival
(P = 0.164).
In group 1 (ODG), we found that TERTp mutations
were not associated with either OS or PFS (P = 0.688
and P = 0.427, respectively) (Fig. 5a). In a combined co-
hort with Groups 2 and 4, TERTp mutation was strongly
associated with patient survival (Fig. 5b), although this
finding may be attributed to the TERTp mutation being
more frequent in the IDH-WT AA group, which has the
worse prognosis than IDH-mutant AA.
In Group 4 (IDH-WT AA), we found that patients
with TERTp-mutant tumor showed shorter median sur-
vival compared to patients with TERTp-WT tumors
[median survival with 95% CI: 8.0 months (0.000–
20.002) vs. 18.1 months (0.000–46.107), respectively];
however, TERTp mutation status did not have an statisti-
cally significant effect on OS or PFS (Table 5, Fig. 5c and
d), possibly because the number of TERTp mutant cases
were too few to attain statistical significance (P = 0.113).
When we evaluated the prognostic value of TERTp mu-
tations in each of the five groups by Cox regression ana-
lysis, we found no evidence of association, with the
exception of Group 5 (IDH-WT GBM), in which we
found by multivariate analysis that patients with TERTp
mutation had statistically worse prognosis than patients
with TERTp-WT (P = 0.045) [median survival with 95%
CI: 16.4 months (13.012–19.516) vs. 13.0 months
(1.021–25.039), respectively] (Table 5). In addition, we
found that having an ATRX mutant tumor did not affect
patient OS or PFS in any of the five groups (all P > 0.05)
(Fig. 6a and b).
From Kaplan Meier survival analysis of diffuse astro-
cytic tumors of grade III and IV, we found that IDH-mu-
tant and younger age-patients (under 55 years of age)
(Figs. 4b-c and 6d) were associated with statistically sig-
nificant better survival compared to their counter parts.
In the IDH-mutant groups (Group 2 and Group 3), be-
cause most patients were younger than 55 years of age,
age was not a factor for patient survival (Table 1) and
particularly in GBMs (combined group 3 and group 5),
the IDH-mutation was exclusively present in the patients
younger than 55 years old.
On multivariate Cox regression analysis of the Group
5 (IDH–WT GBMs), TERT-mutant (P = 0.045), MGMTp
Fig. 3 Electropherograms showing sequence of the TERT promoter region with the two hot-spot mutations a) C250T and b) C228T







No. (%) No. (%) No. (%)
Oligodendroglioma 55/63 (87.3) 8/63 (12.7) 63/65 (96.9)
AA, IDH-mutant 1/1 (100) 0/1 (0) 1/23 (4.4)
GBM, IDH-mutant 7/10 (70) 3/10 (30) 10/13 (76.9)
AA, IDH-wildtype 2/3 (66.7) 1/3 (33.3) 3/15 (20.0)
GBM, IDH-wildtype 36/44 (81.8) 8/44 (18.2) 44/52 (84.6)
Abbreviations: AA anaplastic astrocytoma, GBM glioblastoma, TERTp, TERT
promoter region
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methylation (P = 0.003) and younger age under 55 years
old (P = 0.001) were statistically significant good prog-
nostic factors (Table 5), but in other groups, patients
with TERTp mutation, ATRX mutation, MEMTp
methylation and younger age did not show significantly
different survival rate than counter parts. Regarding age-
related factors, no evidence of statistical significance was
found because of the small number of patients aged
55 years or older with Type III astrocytomas (Fig. 6c).
Discussion
Telomerase is a specialized reverse transcriptase that
maintains telomere length [10]. Telomerase activity is
robustly expressed in embryonic cells, while it is sup-
pressed in fully matured somatic cells during adult life.
However, it is expressed in approximately 85% of solid
tumors and most immortalized cell lines. Recently, sev-
eral studies have reported that TERTp mutations are fre-
quently found in gliomas, especially in ODGs and
GBMs, which results in altered telomere lengthening
and lead to prolonged longevity of tumor cells by escap-
ing from the tumor cell senescence [3]. Aita et al. [19]
found that TERTp mutations are present in >70% of pa-
tients with ODG and GBM, and that the frequency of
TERTp mutation is even higher than previous reports in
ODG and GBM, because the diagnostic criteria of dif-
fuse glioma became more strict with the integration of
genetics in the diagnosis according to the revised 2016
WHO classification criteria.
Based on this finding, we studied the frequency and pu-
tative prognostic importance of mutations in TERTp and
ATRX as well as MGMTp methylation in five patient
groups, which were classified by 2016 revised WHO clas-
sification of CNS tumors: Group 1: ODGs, Group 2: grade
III AA (IDH-mutant), Group 3: grade IV GBM (IDH-mu-
tant), Group 4: grade III AA (IDH-WT), and Group 5:
grade IV GBM (IDH-WT) [19]. These five groups were
well-classified on the basis of OS rate by Kaplan Meier
Survival analysis (Fig. 4a). Patients with IDH-mutant
GBM showed better survival compared to those with
IDH-WT AA and IDH-WT GBM; however, they showed
worse OS than patients with IDH-mutant AA. The OS of
patients with IDH-WT AA was comparable to that found
in patients with IDH-WT GBM. These findings verified
our cohort was not deviated groups.
Furthermore, we found that the TERTp mutation fre-
quencies in these five groups were 96.9%, 4.4%, 76.9%,
20%, and 84.6%, respectively (Table 4). Therefore,
Fig. 4 a) All gliomas included in this study showed statistically different survival. b) Among patients with grade III anaplastic astrocytoma
(AA), the IDH-mutant group showed remarkably better survival than IDH-WT group. c) The IDH-mutant grade IV GBM group had
significantly better survival compared to the IDH-WT GBM group. d) Of all patients with grade III and IV astrocytic tumors, MGMTp-
methylated groups have statistically better survival (P = 0.017). e and f) However, when GBM is subdivided into IDH-mutant and IDH-WT,
MGMTp-methylation has a modest survival effect (P = 0.051 and P = 0.076, respectively). These results indicate there is no bias effect
associated with our group
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patients with grade III IDH-mutant AA (Group 2) had
the lowest incidence of TERTp mutation (4.4%) and pa-
tients with IDH-WT grade III AA (Group 4) had the sec-
ond lowest frequency of TERTp mutation (20%). These
frequencies about half of those reported by Eckel-
Passow et al. [9]. Among their series of grade II or III
gliomas (N = 586), 40.4% (40/99) of IDH-WT astrocy-
toma and 10.1% (31/306) of IDH-mutant astrocytoma
was TERTp-mutated tumors and remained 181 cases
were triple positive (1p/19q co-deleted, IDH-mutant,
and TERT-mutated) ODG [9]. TERT mutation only
cases (that means IDH-WT astrocytomas) were the
worst prognostic group and that group had worse sur-
vival than that of patient with IDH-WT and TERT-WT
[9].
In addition, we found increased frequencies of TERTp
mutations in patients with ODGs and GBMs, both IDH-
mutant and IDH-WT, which is comparable to those
found in a previous report [14]. Therefore, similar to
previously reported studies, we propose that telomerase
activation may be an underlying mechanism in these
gliomas, especially in cases of ODG and GBMs [5]. In
addition, we found that occurrence of the C228T and
C250T mutations were mutually exclusive in our cohort,
and that C228T was more common than C250T (Table
4) [21].
In previous studies, the 1p/19q co-deletion was
strongly associated with mutations in TERTp [13, 25]. In
the present study, we found that 96.9% of patients with
ODG had a TERTp mutation, whereas two patients with
ODG were TERTp-WT (Table 4). However, in cases with
GBM that did not harbor the 1p/19q co-deletion, we
found that they had a high frequency of TERTp muta-
tion, and therefore, conclude that the TERTp mutation is
not exclusively associated with the 1p/19q co-deletion.
Regarding TERTp mutation from a prognostic per-
spective in diffuse gliomas, previous studies showed con-
flicting results. Labussiere et al. found that TERTp
mutations may be associated with poorer outcome in
high-grade gliomas, [16] however, Pekmezci et al. re-
ported that TERT-mutants had significantly worse sur-
vival only in IDH-WT astrocytoma, which includes
Fig. 5 a) In group 1 (ODG), we found that TERTp mutations were not associated with OS (P = 0.688). b) In patients with combined group 2 and 4
(total AAs), TERTp- mutant had poorer survival (p = 0.001) than TERTp-WT patients, due to TERTp mutation was more common in poor prognostic
IDH-WT AA and older age over 55 years old. c) In patients with grade III IDH-WT AA, the TERTp-mutant group shows poorer OS compared to the
TERTp-WT group but was not statistically significant due to shortage of the number of TERTp mutant case (p = 0.113), d) and has no effect on PFS
(p = 0.527). e) In the Kaplan-Meier survival analysis, the TERTp-mutation status in patients with grade 4 IDH-WT has no effect on the patient’s OS
(P = 0.393). f) A similar finding is seen in the IDH-mutant GBM groups (P = 0.370)
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grades II and III [23]. Such contradictory effects of
TERTp mutation on patient outcome between groups
have been reported previously [9]. Abudumijiti et al.
found comparable results to those of Pekmezci et al. and
concluded that adult IDH-WT lower-grade gliomas
should be further classified by TERTp mutation status
[1]. Similarly, our detailed analysis using group classifica-
tions according to IDH-mutation status and multivariate
analysis revealed that only in those cases with grade IV
IDH-WT GBM, TERTp-mutation was associated with
worse OS compared to TERTp-WT (Table 5). We did
not study grade II diffuse astrocytoma because we
wanted a homogeneous group of grade III cases and to
not be potentially biased by grading. In IDH-mutant AA,
the number of TERTp-mutant cases was too small to
evaluate its effect, while in grade IV GBMs, regardless of
IDH-mutation status, TERTp-mutation did not affect pa-
tient OS (Fig. 5c and d). However, it was difficult to ver-
ify this finding in patients with ODG because of the high
frequency of TERTp mutations (96.9%) in this tumor
group. In addition, we found that the MGMTp methyla-
tion group had better survival in combined grade III and
IV astrocytic tumors and in both IDH-mutant and IDH-
WT GBMs; however, we found that ATRX mutation did
not confer a prognostic effect in any of the five groups
evaluated in our study, which is different from Pekmezci
et al.’s conclusion [23].
Our findings differ from those of Eckel-Passow et al.
[9]. They concluded that the patients with grade II or III
gliomas with TERTp mutation only revealed the worst
survival, but TERTp mutation status was not correlated
with survival rate of patients with grade IV glioma. This
result means TERTp mutation may be poor prognostic
marker only in IDH-WT grade II or III astrocytomas.
Further studies incorporating such classification using
molecular alterations including TERTp mutations are
warranted to determine their putative prognostic or
diagnostic importance for gliomas.
Because cancer cells acquire immortality by telomere
lengthening, the telomerase enzyme is a likely anticancer
therapeutic target [10, 24]. Daniel et al. [24] proposed
that the human immunodeficiency virus reverse
transcriptase inhibitor azidothymidine (AZT) acts as a
telomerase inhibitor. In addition, several telomerase-
targeting inhibitors such as the antisense oligonucleotide
inhibitor GRN163L and immunotherapies that use





Median survival years (95%
CI)
Univariate analysis Multivariate analysis
Hazard ratio 95% CI p Value Hazard ratio 95% CI p Value
Group 4
AA, IDH-wildtype 15 51 (26–72) 18.1 (0.000–36.278)
TERTp-mutant 3 69.0 (62–72) 8.0 (0.000–20.002) 0.341 0.85–1.377 1.113 1.11 0.116–10.608 0.928
TERTp-wildtype 12 46.5 (27–58) 18.1 (0.000–46.107)
ATRX-mutant 9 44.5 (27–69) 28.2 (0.954–55.446) 0.555 0.182–1.687 0.299 0.731 0.214–2.498 0.618
ATRX-wildtype 6 54 (41–72) 11.7 (6.733–16.667)
MGMTp-methylated 8 48.5926–62) 28.2 (18.448–37.952) 1.109 0.365–3.367 0.856 1.076 0.261–4.434 0.919
MGMTp-
unmythylated
7 54 (27–72) 7.9 (2.218–13.582)
Age < 55 years old 10 41.5 (26–
54.9)
28.2 (8.676–47.724) 4.027 1.048–15.472 0.043 0.296 0.042–2.107 0.224
Age > 55 years old 5 62 (57–69) 8.0 (7.785–8.215)
Group 5
GBM, IDH-wildtype 52 55 (17–79) 14.5 (10.378–18.622)
TERTp-mutant 41 58 (36–79) 16.4 (13.012–19.516) 0.768 0.390–1.513 0.445 2.111 1.016–4.389 0.045
TERTp-wildtype 11 42 (31–69) 13.0 (1.021–25.039)
ATRX-mutant 5 58 (29–69) 13.0 (0.513–25.547) 0.682 0.269–1.733 0.422 1.269 0.499–3.231 0.617
ATRX-wildtype 47 55 (31–79) 16.4 (12.773–20.027)
MGMTp-methylated 26 57.5 (29–79) 18.3 (12.671–23.989) 0.579 0.326–1.031 0.061 0.665 1.399–5.078 0.002
MGMTp-
unmythylated
26 51 (36–79) 13.0 (9.407–16.653)
Age < 55 years old 24 45 (29–54.9) 20.8 (13.599–28.001) 1.843 1.047–3.331 0.035 3.090 1.578–6.049 0.001
Age > 55 years old 28 67 (55.3–79) 10.5 (5.703–15.297)
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dendritic cells (GRVAC1), the hTERT peptide (GV1001),
or cryptic peptides (Vx-001) are under investigation [24].
Conclusion
In conclusion, mutations in the promoter of TERTp
are common in patients with GBM or ODG. In terms
of survival effect, mutations in IDH1 and MGMTp
methylation and age under 55 were associated with
favorable prognosis in diffuse gliomas and in cases
with grade III AA (combined IDH-mutant and IDH-
WT AA), TERTp mutant carriers had worse OS than
TERTp WT carriers. In multivariate analysis, TERTp
mutation was strongly correlated with poor outcome
in patients with IDH-WT GBM, suggesting that it
may be of prognostic value in this subgroup of pa-
tients with gliomas.
In ODGs, because all tumors have a TERTp mutation
except for two casess, we could not evaluate the putative
prognostic value using the mutation status of this gene.
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